Nuvalent, Inc.
NUVL
Classement en actions
#2103
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Prix de l'action
$123.96
Dernière synchronisation: 2026-07-21
Capitalisation boursière
$9.75B
Changement (1 jour)
0.00%
Changement (1 an)
26.53%
Pays
US
Échange Nuvalent, Inc. (NUVL)
Catégorie
Healthcare
EPS pour Nuvalent, Inc. (NUVL)
EPS au March 2026 TTM : $-6.06
Selon les derniers rapports financiers et le cours de l'action de Nuvalent, Inc., l’EPS actuel de la société (TTM) est de $-6.06. À la fin de 2023, la société avait un EPS de $-2.17 une augmentation par rapport à celui de 2022, qui était de $-1.65.
Historique de l'EPS de Nuvalent, Inc. de 2019 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-6.06 | 54.20% |
| 2024 | $-3.93 | 81.11% |
| 2023 | $-2.17 | 31.52% |
| 2022 | $-1.65 | -22.54% |
| 2021 | $-2.13 | 232.81% |
| 2020 | $-0.64 | 166.67% |
| 2019 | $-0.24 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -385.81% |
US
|
|
| $-7.98 | 31.68% |
US
|
|
| $-5.29 | -12.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -557.76% |
NL
|
